Description of Invention: The present invention comprises peptides/antibodies specific for the binding proteins of Plasmodium, a parasite responsible for malaria, hence in effect blocking the parasite’s binding to the erythrocytes. Also included are methods for their use in preventing, diagnosing or treating the related infections.
Although malaria is virtually eradicated in the United States, it continues to be one of the most serious infectious diseases in the world, killing millions of people each year in the countries throughout Africa, Asia and Latin America. In fact, over 41% of the world population lives in the regions affected by malaria. In vitro studies using the antibodies described in the current technology showed ~80% reduction in the number of blood cells infected with Plasmodium parasite. Infectivity studies using peptides demonstrated that they are also specifically able to prevent binding of parasites to blood cells. The claimed antibodies and peptides can also be used for immunization of humans and animals, or for development of diagnostic kits capable of detecting the presence, localization and quantity of the Plasmodium parasites in tissues and cells.
Inventors: David Narum (Entremed) Kim L Sim (EntreMed, Inc.)
NH Tolia, EJ Enemark, BK Sim, L Joshua-Tor. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 2005 Jul 29:122(2):183-193. [ [PubMed abs] ]
AG Maier, MT Duraisingh, JC Reeder, SS Patel, JW Kazura, PA Zimerman, AF Cowman. Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations. Nat Med. 2003 Jan;9(1):87-92. [ PubMed abs ]
DL Narum, SR Fuhrmann, T Luu, BK Sim. A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol Biochem Parasitol. 2002 Feb;119(2):159-168. [ PubMed abs ]
DCG Mayer, JB Mu, X Feng, XZ Su, LH Miller. Polymorphism in a Plasmodium falciparum erythrocyte-binding ligand changes its receptor specificity. J Exp Med. 2002 Dec 2:196(11):1523-1528. [ PubMed abs ]
BK Sim, DL Narum, H Liang, SR Fuhrmann, N Obaldia 3rd, R Gramzinski, J Aguiar, JD Haynes, JK Moch, SL Hoffman. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med. 2001 Apr;7(4):247-254. [ PubMed abs ]
DL Narum, JD Haynes, S Fuhrmann, K Moch, H Liang, SL Hoffman, BK Sim. Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun. 2000 Apr;68(4):1964-1966. [ PubMed abs ]
H Liang, DL Narum, SR Fuhrmann, T Luu, BK Sim. A recombinant baculovirus-expressed Plasmodium falciparum receptor-binding domain of erythrocyte binding protein EBA-175 biologically mimics native protein. Infect Immun. 2000 Jun;68(6):3564-3568. [ PubMed abs ]
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize "Anti-Plasmodium Compositions and Methods of Use." Please contact Dana Hsu at 301-496-2400 for more information.
For Additional Information Please Contact: Susan Ano Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5515 Fax: 301-402-0220